S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
Log in

NASDAQ:SLNO - Soleno Therapeutics Stock Price, Forecast & News

$3.30
-0.34 (-9.34 %)
(As of 01/27/2020 04:00 PM ET)
Today's Range
$3.26
Now: $3.30
$3.65
50-Day Range
$1.71
MA: $2.66
$3.85
52-Week Range
$1.11
Now: $3.30
$5.07
Volume256,200 shs
Average Volume293,718 shs
Market Capitalization$147.37 million
P/E RatioN/A
Dividend YieldN/A
Beta2.41
Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc and changed its name to Soleno Therapeutics, Inc in May 2017. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLNO
CUSIPN/A
Phone650-213-8444

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.96 per share

Profitability

Net Income$-13,340,000.00

Miscellaneous

Employees9
Market Cap$147.37 million
Next Earnings Date3/16/2020 (Estimated)
OptionableNot Optionable

Receive SLNO News and Ratings via Email

Sign-up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.


Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?

Soleno Therapeutics shares reverse split on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics Inc (NASDAQ:SLNO) issued its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.02. View Soleno Therapeutics' Earnings History.

When is Soleno Therapeutics' next earnings date?

Soleno Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Soleno Therapeutics.

What price target have analysts set for SLNO?

3 equities research analysts have issued 1-year price objectives for Soleno Therapeutics' shares. Their forecasts range from $8.00 to $10.00. On average, they expect Soleno Therapeutics' stock price to reach $9.33 in the next year. This suggests a possible upside of 182.8% from the stock's current price. View Analyst Price Targets for Soleno Therapeutics.

What is the consensus analysts' recommendation for Soleno Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soleno Therapeutics.

Has Soleno Therapeutics been receiving favorable news coverage?

Media stories about SLNO stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Soleno Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Soleno Therapeutics.

Are investors shorting Soleno Therapeutics?

Soleno Therapeutics saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 387,000 shares, an increase of 626.1% from the December 31st total of 53,300 shares. Based on an average trading volume of 244,600 shares, the short-interest ratio is currently 1.6 days. Approximately 1.4% of the shares of the company are sold short. View Soleno Therapeutics' Current Options Chain.

Who are some of Soleno Therapeutics' key competitors?

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Opko Health (OPK), Molecular Templates (MTEM), Agile Therapeutics (AGRX), SCYNEXIS (SCYX), Tetraphase Pharmaceuticals (TTPH), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), AVEO Pharmaceuticals (AVEO), Cidara Therapeutics (CDTX) and Novavax (NVAX).

Who are Soleno Therapeutics' key executives?

Soleno Therapeutics' management team includes the folowing people:
  • Dr. Anish Bhatnagar, Pres, CEO & Director (Age 49)
  • Mr. Anthony Wondka, Sr. VP of R&D (Age 57)
  • Mr. David D. O'Toole, Consultant (Age 60)
  • Mr. Jonathan R. Wolter, CFO & Principal Accounting Officer (Age 69)
  • Dr. Neil M. Cowen Ph.D., MBA, Sr. VP of Drug Devel.

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Lindbrook Capital LLC (0.02%). Company insiders that own Soleno Therapeutics stock include Andrew Sinclair, Bioasia Mangement Llc, Gwen A Melincoff, Jack W Schuler, Larry N Feinberg, Technology Partners Fund Vii L, Ventures Fund V LP Vivo and Vivo Ventures V, Llc. View Institutional Ownership Trends for Soleno Therapeutics.

Which institutional investors are buying Soleno Therapeutics stock?

SLNO stock was purchased by a variety of institutional investors in the last quarter, including Lindbrook Capital LLC. Company insiders that have bought Soleno Therapeutics stock in the last two years include Andrew Sinclair, Gwen A Melincoff, Jack W Schuler and Larry N Feinberg. View Insider Buying and Selling for Soleno Therapeutics.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $3.30.

How big of a company is Soleno Therapeutics?

Soleno Therapeutics has a market capitalization of $147.37 million. The company earns $-13,340,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Soleno Therapeutics employs 9 workers across the globe.View Additional Information About Soleno Therapeutics.

What is Soleno Therapeutics' official website?

The official website for Soleno Therapeutics is http://www.soleno.life/.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]


MarketBeat Community Rating for Soleno Therapeutics (NASDAQ SLNO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  254 (Vote Outperform)
Underperform Votes:  195 (Vote Underperform)
Total Votes:  449
MarketBeat's community ratings are surveys of what our community members think about Soleno Therapeutics and other stocks. Vote "Outperform" if you believe SLNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel